Fast-track neural cell production with iPSC differentiation kits

AMSBIO has launched a comprehensive range of Quick-Neuron™ differentiation kits, designed to simplify and accelerate the generation of specific neural cell types from human induced pluripotent stem cells (iPSCs). These kits provide researchers with a fast, consistent, and animal-free approach to producing high-purity neurons - enabling more efficient disease modelling, drug screening, and regenerative medicine studies.

Each kit includes a streamlined, highly reproducible protocol that allows users to generate functional neural cell types within just 1–2 weeks. The easy-to-follow workflows are ideal for labs seeking standardisation without compromising cell quality or reproducibility. Importantly, the differentiation process avoids the use of animal-derived materials and leaves no genetic footprint, thanks to a proprietary non-integrating transcription factor-based method available in either Sendai virus or synthetic mRNA format.

For added convenience, AMSBIO also offers a range of pre-differentiated cell lines – both diseased and healthy controls – for each neuron type, allowing users to bypass the initial iPSC steps if desired.

The Quick-Neuron™ Excitatory Differentiation Kit produces high-purity glutamatergic neurons expressing key markers including TUBB3 and vGLUT1. These neurons exhibit typical neurite outgrowth, and electrophysiological analysis via patch clamp confirms spontaneous action potential generation.

The Dopaminergic Differentiation Kit enables rapid mRNA-driven production of dopaminergic neurons expressing TH and TUBB3. Likewise, the GABAergic Differentiation Kit delivers robust populations of inhibitory neurons within 10 days, validated by expression of appropriate markers and neuronal morphology. AMSBIO also supplies ready-made human iPSC-derived GABAergic neurons for immediate use.

Rounding out the collection, the Cholinergic Differentiation Kit allows for fast and efficient generation of cholinergic neurons expressing TUBB3 and ChAT, supporting applications in both neurodegenerative disease research and drug development.

All kits are based on human iPSCs made under licence from the California Institute for Regenerative Medicine (CIRM), providing quality and consistency aligned with translational research goals.

These versatile, scalable tools empower researchers working at the interface of neuroscience, genomics, and biotechnology to produce defined human neural cells quickly and reliably - all without relying on animal models.

More information online